THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES;KITE PHARMA; INC.;KITE PHARMA, INC.
发明人:
PEREZ, ARIANNE,SABATINO, MARIANNA,ROSENBERG, STEVEN A.,RESTIFO, NICHOLAS P.
申请号：
CA3001613
公开号：
CA3001613A1
申请日:
2016.10.20
申请国别(地区):
CA
年份:
2017
代理人:
摘要：
Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.
